Top Results For: wegovy

Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result in more generics and hurt sales.

Health Canada is warning Canadians of the dangers of buying "fake or unauthorized products" meant to replicate popular GLP-1 drugs such as Ozempic, Rybelsus and Wegovy.

The pill was approved by the U.S. Food and Drug Administration last month, a boon to Novo Nordisk as it looks to regain ground lost to U.S. rival Eli Lilly.

The FDA approved the one-a-day Wegovy pill, the first oral GLP-1 medication for obesity in the U.S., Wegovy manufacturer Novo Nordisk said in a statement Tuesday.

As of Dec. 29, Health Canada had received nine submissions seeking approval to make semaglutide, the active ingredient in Ozempic and Wegovy.

The approval gives Novo Nordisk a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly.

Negotiations that could have led to coverage for weight-loss drug Wegovy under Canadian public health plans are not moving forward.

The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.

People on average regain weight at a rate of 0.4 kg/month after they stopped taking their weight loss medications, a review of 63 trials covering over 9,000 individuals showed.

Trump, Eli Lilly and Novo Nordisk unveiled a deal to slash the prices of popular GLP-1 weight‑loss drugs for government health insurance programs, as well as for cash payers.

NEW YORK (AP) — U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss treatments Ozempic and Wegovy.

WASHINGTON (AP) — President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for the popular obesity treatments Zepbound and Wegovy.

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Ozempic and Wegovy maker Novo Nordisk says it will layoff about 9,000 employees of its global workforce as it restructures in an attempt to fend off competition.

Brooke Sears fought to get her diagnosis after doctors said she needed to lose weight. Her story is part of a Global News series on health care and how it's failing many women.

The patients taking the drug were also less likely to die from cardiovascular disease — another condition that affects many patients with diabetes.

Researchers at the University of Manitoba are looking at how marketing for drugs like Ozempic and Wegovy influence peoples' views on food, hunger, and weight.

Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide.

A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.